Discontinuation of Antithrombotic Management Following Left Atrial Appendage Occlusion in High Bleeding Risk Patients
Catheterization and Cardiovascular Interventions · 2025
DOI: 10.1002/ccd.70014 ↗At a glance
Journal article in Catheterization and Cardiovascular Interventions, 2025. Written by Siu-Fung Wong and 8 co-authors. Institution: Department of Cardiology, Sussex Cardiac Centre, University Hospitals Sussex, Brighton, UK. Major MEDLINE topics: Atrial Appendage, Atrial Fibrillation, Hemorrhage, Fibrinolytic Agents. 30 references. Funded by: The authors received no specific funding for this work..
Abstract (original language)
Background
Antithrombotic therapy is required after left atrial appendage occlusion (LAAO) whilst endothelialization of the device occurs. LAAO patients are usually at high bleeding risk and the optimal antithrombotic regimen post‐implantation remains debated.
Aims
We aimed to study the efficacy of using maximum of 6‐month antithrombotic treatment post‐LAAO in high bleeding risk patients with atrial fibrillation.
Methods
Data from patients who had LAAO at our center between 2015 and 2024 were examined. Those who were discharged on a plan of 6 months antithrombotic therapy were included. Incidence of stroke, transient ischaemic attack (TIA), major bleeding or death during follow‐up was measured.
Results
A total of 128 patients met the analysis criteria. One hundred and six (82.8%) patients had a previous major bleeding event with or without oral anticoagulation. Seventy‐eight (60.9%) patients had a previous stroke. The median CHA 2 DS 2 ‐VASc and HAS‐BLED scores were 4 and 3 respectively. Complete closure of the left atrial appendage was achieved in 116 (90.6%) patients with no peri‐device flow. Follow‐up was obtained for 484 patient‐years (median follow‐up time 3.6 years). Post‐procedure, 126 (98.4%) patients had antiplatelet therapy only, for 6 months or less. Stroke or TIA occurred in 5.5% of patients (1.45 per 100 patient‐years)—a 69% reduction compared to the predicted risk. 10.2% of patients suffered from major bleeding (2.69 per 100 patient‐years). 36.7% (9.71 per 100 patient‐years) of patients died.
Conclusion
Complete cessation of antithrombotic treatment 6 months after LAAO was associated with a low incidence of subsequent stroke or TIA in patients at high bleeding risk.
Subjects
MeSH terms (MEDLINE)
Author keywords
Substances
Authors and institutions
- Department of Cardiology, Sussex Cardiac Centre, University Hospitals Sussex, Brighton, UK.
- St Vincent's Heart Centre, St Vincent's Hospital Melbourne, Melbourne, Australia.
- Department of Anaesthesia, Royal Sussex County Hospital, Brighton, UK.
ORCID profiles: Siu-Fung Wong, Timothy Bagnall
Funding
- The authors received no specific funding for this work.
Cite
APA
Wong, S. F., McCready, J. W., Cockburn, J., Broyd, C., Bagnall, T., Arunothayaraj, S., Gomes, A., Hill, A., & Hildick-Smith, D. (2025). Discontinuation of Antithrombotic Management Following Left Atrial Appendage Occlusion in High Bleeding Risk Patients. Catheterization and Cardiovascular Interventions. https://doi.org/10.1002/ccd.70014
Vancouver
Wong SF, McCready JW, Cockburn J, Broyd C, Bagnall T, Arunothayaraj S, et al. Discontinuation of Antithrombotic Management Following Left Atrial Appendage Occlusion in High Bleeding Risk Patients. Catheterization and Cardiovascular Interventions. 2025. doi:10.1002/ccd.70014
BibTeX
@article{Wong2025,
author = {Wong, Siu-Fung and McCready, James W and Cockburn, James and Broyd, Christopher and Bagnall, Timothy and Arunothayaraj, Sandeep and Gomes, Arionilson and Hill, Andrew and Hildick-Smith, David},
title = {Discontinuation of Antithrombotic Management Following Left Atrial Appendage Occlusion in High Bleeding Risk Patients},
journal = {Catheterization and Cardiovascular Interventions},
year = {2025},
doi = {10.1002/ccd.70014}
}
EUVIMED